Lineage Cell Therapeutics Inc. — Director's Dealing 2014

Mar 25, 2014

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIOTIME INC (BTX)
CIK: 0000876343
Period of Report: 2014-03-20

Reporting Person: TEW WILLIAM P PHD (Chief Commercial Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2014-03-20	Option to Purchase Common Shares	$3.51	J	100000	Acquired	2021-03-19	Common Shares (100000)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Shares, no par value	33265	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Option to Purchase Common Shares	$4.22	2020-02-19	Common Shares (100000)	100000	Direct
Option to Purchase Common Shares	$4.17	2018-10-02	Common Shares (3850)	3850	Direct
Option to Purchase Common Shares	$7.47	2018-03-20	Common Shares (25000)	25000	Direct
Warrant to Purchase Common Shares	$10.00	2014-05-02	Common Shares (29247)	29247	Direct

Footnotes

F1: Does not include shares that may be acquired upon the exercise of certain stock options, and shares that may be acquired upon the exercise of certain warrants.

F2: 1/48th of the number of options will vest and become exercisable at the end of each full month of employment after March 20, 2014.

F3: 1/48th of the number of options will vest and become exercisable at the end of each full month of employment after January 1, 2013.

F4: 1/48th of the number of options will vest and become exercisable at the end of each full month of employment after October 4, 2011.

F5: 1/48th of the number of options will vest and become exercisable at the end of each full month of employment after March 21, 2011.